FREXALT: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 6, 2026 - P3 | N=1655 | Active, not recruiting | Sponsor: Sanofi | -> Active, not recruiting
Enrollment closed • CNS Disorders • Multiple Sclerosis • NEFL • Plasma NfL
|